News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: Lirumlarum1

IBRX on X: #ICYMI: @urotoday published an informative piece on the current treatment landscape of BCG-unresponsive non-muscle invasive #bladdercancer. Read on to learn more about N-803 and viral/bacterial-based therapies: https://urotoday.com/library-resources/bladder-cancer/146405-library-resource-the-current-treatment-landscape-of-bcg-unresponsive-non-muscle-invasive-bladder-cancer-n-803-and-viral-bacterial-based-therapies.html…

https://www.syneoshealth.com/careers/jobs/13319712-uro-oncology-business-manager

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-biological-license-application?field_nir_news_date_value[min]=

IL-15 and N-803 for HIV Cure Approaches https://pubmed.ncbi.nlm.nih.gov/37766318/

Besitzverhältnisse: https://ir.immunitybio.com/node/10006/html

ImmunityBio Ready To Invest In Area Plant https://www.post-journal.com/news/local-news/2023/09/immunitybio-ready-to-invest-in-area-plant/

After FDA rejection, ImmunityBio lays off staff in California and Florida https://www.fiercebiotech.com/biotech/after-fda-rejection-immunitybio-lays-staff-california-and-florida

Form 4 ImmunityBio, Inc. For: Sep 11 Filed by: SOON-SHIONG PATRICK https://www.streetinsider.com/dr/news.php?id=22159510

http://www.urotoday.com/library-resources/bladder-cancer/146405-library-resource-the-current-treatment-landscape-of-bcg-unresponsive-non-muscle-invasive-bladder-cancer-n-803-and-viral-bacterial-based-therapies.html

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-470-million-equity-and-debt-financing?field_nir_news_date_value[min]=

8K Report: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000112/0001326110-23-000112-index.htm

ImmunityBio: Ongoing Dilution And Regulatory Uncertainties Blur Investment Prospects https://seekingalpha.com/article/4626174-immunitybio-ongoing-dilution-and-regulatory-uncertainties-blurry-investment-prospects?mailingid=32362304&messageid=must_reads&serial=32362304.2814921&utm_campaign=Must%2BReads%2Brecurring%2B2023-08-10&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads

Immunitybio Inc reports results for the quarter ended in June - Earnings Summary https://www.xm.com/research/markets/allNews/reuters/immunitybio-inc-reports-results-for-the-quarter-ended-in-june-earnings-summary-53612229

ImmunityBio Names Enrique Diloné as Chief Technology Officer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-names-enrique-dilone-chief-technology-officer?field_nir_news_date_value[min]=

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-execution-40-million-equity-financing?field_nir_news_date_value[min]=